Combining cell cycle checkpoint kinase inhibitors with the DNA-damaging chemotherapeutic agent gemcitabine offers clinical appeal, with a mechanistic rationale based chiefly on abrogation of gemcitabine-induced G2/M checkpoint activation. However, evidence supporting this mechanistic rationale from chemosensitization studies has not been consistent. Here we report a systematic definition of how pancreatic cancer cells harboring mutant p53 respond to this combination therapy, by combining mathematical models with large-scale quantitative biological analyses of single cells and cell populations. Notably, we uncovered a dynamic range of mechanistic effects at different ratios of gemcitabine and CHK1 inhibitors. Remarkably, effective synergy was attained even where cells exhibited an apparently functional G2/M surveillance mechanism, as exemplified by a lack of both overt premature CDK1 activation and S-phase mitotic entry.
INTRODUCTION
The DNA damage response (DDR) to a vast majority of genomic insults is orchestrated by the activation of two key phosphatidylinositol 3-kinase-related kinases, ATM and ATR. Upon recruitment to damage sites, ATM and ATR phosphorylate a number of substrates, including checkpoint kinase CHK1 (CHEK1), which in turn mediate cell cycle arrest to facilitate DNA repair (1) . An intact ATM/ATR-CHK1 signaling cascade is integral to genomic integrity and therefore survival. Because cancer cells frequently harbor surveillance defects, they are reliant on the residual functional processes of the DDR machinery (2) . Inhibition of the DDR with checkpoint kinase inhibitors thus heralds a promising cancer therapeutic strategy for chemosensitization.
Early prototypes of non-selective checkpoint kinase inhibitors caffeine and UCN-01
have been shown to induce unscheduled mitosis following abrogation of DDRinduced cell cycle arrest (3, 4) . This has subsequently inspired an accumulating body of evidence associating CHK1 inhibition with G2/M checkpoint abrogation, characterized by premature chromosomal condensation, inflated mitotic index and aberrant chromosomal structures (5) (6) (7) . Against this background, ongoing clinical trials of CHK1 inhibitors with DNA-damaging agents are chiefly based on the notion of G2/M checkpoint abrogation (8) . Nonetheless, owing to the multiple roles of CHK1 in cell cycle regulations, it is not definitive if this represents the predominant mechanism of chemosensitization (9) .
Among all chemotherapy agents, the greatest potentiation by CHK1 inhibitors has been reported with antimetabolites, notably gemcitabine (10) . Gemcitabine is standard for patients with pancreatic ductal adenocarcinoma, one of the most intractable of human malignancies (11) . Here, we took a systematic approach to 4 elucidate how pancreatic tumor cells responded to gemcitabine and CHK1 inhibition.
Using mathematical models coupled with cytotoxicity assays, we first identified concentration ratios of gemcitabine and CHK1 inhibitors that induced synergistic growth inhibition. We then employed population-and single-cell-based assays to quantitatively define cell cycle modulation and cell behaviors. Our study reveals a level of mechanistic complexity that offers conceptually important insights into the dynamic interplay between gemcitabine and CHK1 inhibition. 
MATERIALS AND METHODS

Cell culture and chemicals
Human pancreatic cancer cells (MIA PaCa-2, Panc-1), colorectal cancer cells (HT-29) and non-malignant lung fibroblast (IMR-90) were obtained from either the European Collection of Cell Cultures or the American Type Culture Collection. They were authenticated using either Promega GenePrint10 system or Promega PowerPlex 16HS kit, and were grown in DMEM with 10% FBS (GIBCO). Murine pancreatic cancer cells K8484 were established from a KRas G12D ; p53 R172H ; Pdx1-Cre mouse (12) and were grown in DMEM with 5% FBS. All cell lines were grown up to a maximum of 20 passages and for fewer than 6 months following resuscitation.
They were routinely verified to be mycoplasma-free using the Mycoprobe hours. To analyze cell cycle distributions, cells were trypsinized, fixed with either 70% ethanol or 4% paraformaldehyde, stained with antibodies and counterstained with propidium iodide. Samples were analyzed on the BD FACSCalibur flow cytometer (BD Biosciences). ≥10000 events were collected per sample, and data were processed using the FlowJo software.
Mycoplasma Detection Kit (R&D Systems
)
Clonogenic assay
Cells were plated 24 hours prior to treatment. Following treatment, equal numbers of viable cells from each sample were reseeded in fresh medium and left to grow.
Seven days later, cells were fixed with 70% methanol and stained with 5% Giemsa (Sigma-Aldrich). Colonies were imaged and quantified using the ImageQuant TL software (GE Healthcare). Plating efficiency was calculated from the ratio of the number of colonies to the number of cells seeded. The number of colonies that arose after treatment was expressed as surviving fraction. This was derived from the ratio of the number of colonies formed after treatment to the number of cells seeded multiplied by plating efficiency of the control.
Immunostaining and immunoblotting
For immunostaining, cells were fixed with 4% paraformaldehyde, permeabilized with 0.3% Triton X-100, stained with antibodies and counterstained with DAPI. To visualize centromeres and kinetochores, 100% methanol fixation method was used.
EdU and TUNEL Click-it assays were performed on paraformaldehyde-fixed samples based on Click-it reaction according to manufacturer's instructions (Life Technologies). For immunoblotting, whole-cell extracts were obtained by lysis in RIPA buffer (50mM Tris pH8.0, 2mM EDTA, 150mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) and resolved using the SDS-PAGE gel system (Life Technologies). Blots were analyzed using the Odyssey Infrared Imaging System (LI-COR). Images were acquired with the IncuCyte Live Cell Imaging microscopy (Essen Bioscience) at every three hours under cell culture conditions with 10X objective.
IncuCyte time-lapse imaging
Averaged cell confluence was calculated from three random fields of view per well using the IncuCyte in-built algorithm. Relative confluence values were obtained by normalizing each value to the time zero value in each sample.
Metaphase spreads
Cells were treated with 0.1ug/mL colcemid for 45 minutes, trypsinized and treated in a drop-wise manner with pre-warmed 0.075M KCl. After 15-minute incubation at 37°C, cells were sequentially fixed in freshly prepared methanol:acetic acid mix (3:1 then 3:2). After an overnight incubation at -20°C, cells were dropped onto coverslips and stained with ProLong® Gold Antifade Mountant with DAPI (Life Technologies).
Statistical analyses
Data were analyzed using the GraphPad Prism built-in tests. For comparison among three or more groups, an ordinary one-way ANOVA analysis followed by post hoc tests was performed. The following asterisk rating system for p-value was used: *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. 
Supplementary Materials and
RESULTS
Mathematical modelling identifies effective synergy between gemcitabine and
CHK1i at sub-GI 50 concentrations A drug discovery program identified S1181 as a novel selective small molecule inhibitor of CHK1 (IC 50 =2.5nM) (Fig. 1A, Supplementary Fig. S1A , Table S1 ). Using S1181 as a CHK1i tool compound, we performed sulforhodamine B cytotoxicity assays to test its effects with gemcitabine on human cancer cell lines (MIA PaCa-2, Panc-1, HT-29) and a mouse pancreatic cancer cell line, K8484, obtained from a Target inhibition occurred at synergistic concentrations, as demonstrated by attenuation of CHK1 autophosphorylation at S296 and phosphorylation of ATR targets CHK1 S317 and CHK1 S345 (Fig. 1C, Supplementary Fig. S1C ) (13) . With 24 hours of combination treatment, ATM S1981 nuclear foci were observed, alongside the upregulation of its downstream substrates CHK2 T68 and H2AX S139 (yH2AX), implying elevated DNA damage that involved fork breakage (Fig. 1C-D) .
With 72 hours of combination treatment, cell viability was severely affected, as evidenced by increase in yH2AX, cleaved PARP and caspase-3, apoptotic bodies, and TUNEL staining ( Supplementary Fig. S1D-F corroborated a durable synergistic relationship between the two agents (Fig. 1E,   Supplementary Fig. S1G ). Together, the data demonstrate that sub-GI 50 concentrations of gemcitabine and CHK1i are sufficient to yield synergistic growth inhibition.
Forced mitotic entry is not a common determinant of effective synergy
A widely held assumption is that CHK1 inhibition abrogates the G2/M checkpoint by triggering inappropriate CDK activation, leading to forced mitotic entry. To test this notion in the context of effective synergy, we interrogated CDK activation status ( Fig.   2A ). Unexpectedly, we found no apparent disinhibition of CDK activity (i.e. no decrease in the inactive form CDK Y15) upon gemcitabine+CHK1i treatment at synergistic concentrations. To rule out potential off-target effects of S1181, we used another structurally distinct potent CHK1-specific inhibitor CHIR-124 and achieved similar outcomes at relevant synergistic concentrations ( Supplementary Fig. S2A-B) .
We investigated if these molecular changes were accompanied by forced mitosis.
Both quantitative immunoblotting and cytometry for mitotic marker HH3 S10 (pHH3) confirmed that the synergistic combination did not substantially elevate the mitotic population compared to single-agent controls ( Fig. 2A, Supplementary Fig. S2C ).
Furthermore, DNA content of the mitotic cells treated with the synergistic concentrations was near 4N regardless of treatment duration (24-72 hours), suggesting an absence of forced S-phase mitotic entry ( Fig. 2B and Supplementary   Fig. S2D ; see data for 10nM gemcitabine+1uM S1181).
Cancer cells display divergent mechanistic interpretations at different concentration ratios
A potential caveat of the above findings is that they were attained under fixed-ratio of gemcitabine and CHK1i, and thus did not capture the dynamic range within which (1uM), the percentage of mitotic cells was not considerably different from singleagent controls and they had ~4N DNA content; with high gemcitabine (300nM) and CHK1i (5uM), there was an increase in <4N mitotic cells. Collectively, while our data are in line with previous reports on G2/M checkpoint abrogation at relatively high concentrations of gemcitabine or CHK1i, they argue for the hitherto discounted possibility that this is dispensable at optimal synergistic ratios of gemcitabine and CHK1i.
Delayed S progression is a denominator of cytotoxicity, regardless of the mode of elimination
The foregoing experiments suggest that forced mitotic entry is inadequate to explain the effective synergy between gemcitabine and CHK1i. First, the principle of effective checkpoint abrogation would apply if cells experience supra-physiological levels of DNA damage in the first instance; such was not the case with sub-GI 50 gemcitabine alone ( Fig. 1, Fig. 2 ). Second, cells treated with gemcitabine at synergistic concentrations in the absence of CHK1i remained cycling for at least 72 hours, incongruent with the notion of an alarmed G2/M checkpoint ( Supplementary Fig.   S3A ). Third, given the nominal extent of checkpoint activation, checkpoint abrogation by CHK1i would be more a conditional than an absolute requirement for synergy, explaining the absence of overt perturbation on CDK1 activity (Fig. 2 ).
To validate these conclusions, we reasoned that there must be a mechanistic underpinning that preceded G2/M checkpoint abrogation. We performed quantitative flow cytometry to determine cell cycle profiles. Consistently, gemcitabine+CHK1i at synergistic concentrations resulted in an increase in S-phase population ( (Fig. 3B) . Gemcitabine+CHK1i prolonged the interphase residence time by another 3 hours (13.3 ± 0.53h), consistent with the accumulation of the S-phase population (Fig. 3A) .
Time-lapse analysis showed diverse cell fates following gemcitabine+CHK1i (Fig.   3C ). To facilitate comparative analyses without compromising the complexity, the first-generation fate profile of each individual cell from the time of treatment to the end of first mitosis (if occurred) was plotted (Fig. 3D) . Of the 115 asynchronous cells, eighty-three cells proceeded to the next cell cycle while thirty-two cells experienced adverse fate in the first observed cell cycle. Among these thirty-two cells, two died in mitosis, fifteen failed cytokinesis, while the remaining fifteen experienced prolonged arrest (three), senescence (seven) or death (five) in S/G2 interphase without ever entering mitosis. Notably, twenty-three out of twenty-nine cells in the fourth quartile of S/G2 duration experienced adverse fates. All these data stood in contrast to the first-generation fate profiles of the control, where all the 100 cells entered mitosis following a relatively short S/G2 duration and successfully underwent cytokinesis ( Supplementary Fig. S3D ). Together, these data support a model where, irrespective of how a cell is eliminated, prolonged S duration appears to be a key that presages an unfavorable biological event. ( Supplementary Fig. S3E ). We tracked cells that underwent one mitotic division in order to identify daughter cells derived from the same mother. We then determined the fate of 75 pairs of sisters. We found that most sisters shared the same fate upon gemcitabine+CHK1i. Based on this and our earlier results, we reasoned that cell fate decision could be dependent on the degree of maternal exposure during S/G2. Strikingly, we found that offspring of mothers with protracted S/G2 progression were more prone to some form of adverse fate (failed cytokinesis, interphase arrest, senescence, death) than those with mothers of shorter S/G2 duration (Fig. 3E) .
Furthermore, linearity between the S/G2 duration and mitotic duration implies a causal connection between the interphase state and subsequent mitotic state, providing an explanation to previous work that implicates CHK1i in activating the spindle assembly checkpoint (16) .
Next, we asked if S/G2 duration progressively lengthened through generations. To address this in a manner that ensured complete retrieval of temporal data, we focused on cells that were in G1 phase at the start of each experiment and that had at least one dividing daughter. Significantly, S/G2 duration doubled over two generations (Fig. 3F ). This was accompanied by a five-fold increase in mitotic duration ( Supplementary Fig. 3SF ). Furthermore, virtually all second-generation cells affected by the temporal inflation failed to divide, consistent with the phenomenon seen in the first-generation population. As a unifying validation to all our findings, we 
length of S/G2 and mitosis, with those cells at the higher ends being more vulnerable to cytokinesis failure ( Supplementary Fig. 3SH ). Together, our lineage-tracing analyses highlight the effects of agent exposure during interphase and how that could propagate across the descendants of an insulted cell.
CHK1 inhibition triggers global replication stress by deregulating the replication checkpoint
The distinctive phenotype of perturbed S progression prompted us to interrogate the intra-S replication activity upon treatment. Fig. S4A ). Collectively, the data suggest enforced initiation and promotion of DNA synthesis with CHK1 inhibition.
Forced DNA synthesis is a source of replication stress (17) . In response to replication stress, single-stranded DNA (ssDNA)-coating trimeric RPA protein is recruited and phosphorylated at multiple sites, with RPA32 S4/8 being found in the most hyper-phosphorylated form of the protein (18) . We observed an increase in phosphorylated RPA upon gemcitabine+CHK1i treatment but not with either agent alone ( Supplementary Fig. S4B ). This exclusivity highlights the dependency between 
the two agents in deregulating the replication program. Furthermore, quantitative microscopy reveals that cells with the highest degree of RPA32 S4/8 were also experiencing substantial fork breakage, as evidenced by co-staining with yH2AX (Fig. 4B, Supplementary Fig. S4C ). The majority of these cells were in S-phase (Supplementary Fig. S4D ). High-resolution confocal imaging shows nucleus-wide staining of activated RPA in these cells, indicative of long stretches of ssDNAs with stalled replication forks (Supplementary Fig. S4E ). On the other hand, yH2AX was found in heterochromatic regions, consistent with the presence of replication intermediates refractory to repair (19) . Together, the data suggest that gemcitabine+CHK1i overloads the replication machinery through improper initiation and promotion of DNA synthesis, eventually leading to the pathological outcome of unresolved DNA lesions.
A reverse prediction was that suppression of DNA synthesis should relieve global replication stress. To this end, we exploited the paradigm that CHK1 regulates origin activity and that origin activity requires CDK2 (20) . We found that application of a broad CDK inhibitor roscovitine with gemcitabine+CHK1i reversed S-phase accumulation within 12 hours (Fig. 4C) . By 24 hours, roscovitine markedly subdued yH2AX and RPA32 S4/8 expressions in treated cells, indicating mitigation of replication stress (Fig. 4D) . These results were reproduced by inhibiting Cdc7, another regulator of origin firing (Fig. 4C-D) .
Given that inhibition of CDKs and Cdc7 is cytostatic, a counter-argument would be that the apparent rescue was an indirect effect of reduced genome incorporation of gemcitabine. To address this, we asked whether restraining DNA replication in gemcitabine+CHK1i could abolish the synergistic growth inhibition. We performed long-term proliferation studies (Fig. 4E, Supplementary Fig. S4F ). Significantly, cell proliferation was restored to control levels by roscovitine and Cdc7i, partially or fully so depending on cell lines. Substituting roscovitine with a specific CDK1i at subarresting concentrations did not redress growth retardation by gemcitabine+CHK1i (Supplementary Fig. S4G ). Together, these data show that, at sub-GI 50 concentrations, CHK1i synergizes with gemcitabine mainly by perturbing the Sphase homeostasis through deregulated DNA replication, not by G2/M checkpoint abrogation.
Mitotic aberrance is a consequence of deranged replication machinery
Emerging evidence suggests that genomic insults in interphase can persist into mitosis (21) . Given that a fraction of cells underwent prolonged mitosis upon gemcitabine+CHK1i, we proceeded to determine the nuclear morphology of these cells. Aberrant mitotic architectures were significantly found in the combination treatment ( Fig. 5A-B) . These included misaligned metaphases, lagging chromosomes and anaphase bridges. When cells were synchronized at the G2/M border and released into gemcitabine+CHK1i, there was no evidence of gross mitotic aberrance ( Supplementary Fig. S5A ). This ruled out the possibility that CHK1 mitotic role was compromised (22) . Together, the data suggest that preceding replication mishap is responsible for the aberrant mitotic manifestations.
We noticed that misaligned metaphases with dramatic dispersion of chromosomes were particularly common with CHK1 inhibition. Previous studies have invariably attributed this feature to checkpoint bypass, but have variously described it as disorganized spindle (23), centromere fragmentation (24) and failure of chromosomes with intact centromeres to align along the metaphase plate (14) . To clarify, we stained cells for tubulin and found apparently normal bipolar microtubule organization (Fig. 5A) . With z-stack confocal analysis, we found core component of kinetochore outer plate HEC1 co-localizing exclusively with chromosomes at the metaphase plate (Fig. 5C ). This was accompanied by the presence of genome material separate from the plate, indicative of acentric chromosomes. Similar spatial configuration was also observed with centromere DNA-binding CENP-B. Given that (peri)centromeric structures arise from heterochromatin, damage in this region would conceivably result in their defective formation. This is consistent with the observation that only with CHK1 inhibition (with or without gemcitabine) did yH2AX propagate into heterochromatin (Supplementary Fig. S5B ).
An alternative but not mutually exclusive explanation was chromosomal fragmentation, a phenomenon increasingly recognized as a form of mitotic death but often confused with premature chromosomal condensation (PCC) (25) . To formally investigate this possibility, we performed immunofluorescence and found that (1) yH2AX decorated aberrant mitoses, more so in those with severely tattered chromosomes (Fig. 5D ), (2) mitoses were EdU-negative and were not actively replicating (Fig. 5E) , and (3) mitotic aberrance was not abolished by CDK inhibitor co-treatment ( Supplementary Fig. S5C ). Furthermore, independent of combination treatment duration (24-72 hours), metaphase spreads showed various stages of chromosomal breakage demonstrated by differential cut sizes, suggesting that it was a cumulative process that occurred at single-cell level (Fig. 5F ). Together, these data confirm chromosomal fragmentation, preclude PCC (26) We have shown that the immediate response of cells upon addition of CHK1i to gemcitabine at lower, synergistic concentrations is not premature S-phase mitotic entry. Instead, cells experience prolonged interphase with enhanced DNA damage and replication stress, reminiscent of the nucleus-wide replication catastrophe when ATR signaling is perturbed (30) . A fraction of these cells enter mitosis, often with disastrous consequences. While this in principle suggests G2 abrogation, given the global mitotic CDK1 suppression and substantial delay in mitotic entry as well as the low concentrations of the agents used, the data are also compatible with the notion of G2 checkpoint adaptation. It has been shown that G2 adaptation can occur in human cells and is possible following pharmacological concentrations of genotoxic agents (31, 32) . Taken together, as opposed to blatant checkpoint abrogation, our study illustrates a "foot-in-the-door" phenomenon (Fig. 6B) . This model proposes that premature S-phase mitotic entry is not the predominant route to chemosensitization.
Instead, CHK1i synergizes with gemcitabine via a more subtle and far-reaching mechanism, i.e. first by engaging cells in disorderly replication, then committing them to elimination processes that could take place in and beyond mitosis.
Our mechanistic study raises several key issues regarding the development of 
promising clinical trial so far, two patients with pancreatic adenocarcinoma exhibited stable disease lasting > 10 months, and there was a partial response in a cholangiocarcinoma patient, in a Phase I dose escalation study, when CHK1i MK-8776 was given only 30 minutes after gemcitabine (34). We have shown with the aid of mathematical models that non-cytotoxic concentrations of gemcitabine and CHK1i could yield effective synergy in tumor cells when given together. We propose that simultaneous administration of both agents warrants further investigation. This is especially germane in view of the variable intratumoral gemcitabine levels expected in patients, owing to short half-life and poor drug delivery (12) . Second, dosedependent toxicities are a major cause of drug attrition. Clinical development of several checkpoint kinase inhibitors has been discontinued, the most recent being AZD7762 given its untoward cardiotoxicity (35). We have shown that a threshold of CHK1 inhibition beyond that necessary for synergy is required for overt checkpoint abrogation. As our data suggest that inhibition of S-phase activities of CHK1 is more relevant to chemosensitization, concurrent administration of gemcitabine and CHK1i would in principle obviate the need for G2/M checkpoint abrogation. We anticipate that metronomic gemcitabine, where low doses are given at frequent intervals, represents an opportunity where the synergistic interaction between the antimetabolite and CHK1i could be exploited (36). Third, low doses of gemcitabine and CHK1i would permit the possibility of triple drug therapies. This is potentially applicable to treatment modalities to which S-phase cells are particularly vulnerable, for example radiotherapy. In support of this and the notion that G2/M bypass is dispensable for synergy, radiosensitization has been reported to occur most optimally when CHK1 is inhibited during S-phase, but not when G2/M abrogation is 
